Overview

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Status:
Not yet recruiting

Trial end date:
2025-08-29

Target enrollment:

Participant gender:

Summary

Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.

Phase:

Phase 1

Details

Lead Sponsor:

HonorHealth Research Institute

Collaborator:

NovoCure Ltd.

Treatments:

Ipilimumab
Nivolumab